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esponsibility of Xi'aAbstract A simple, sensitive and speciﬁc liquid chromatography–tandem mass spectrometry method was
developed for simultaneous quantiﬁcation of ezetimibe and simvastatin in rat plasma. The deuterium isotopes:
ezetimibe d4 and simvastatin d6 were used as internal standards for ezetimibe and simvastatin, respectively.
MS/MS detection involved a switch of electron spray ionization mode from negative to positive at retention
time 3.01 min. Samples were extracted from plasma by liquid–liquid extraction using tertiary butyl methyl
ether. Chromatographic separation was achieved with Agilent Eclipse XBD-C18 column using mobile phase
that consisted of a mixture of ammonium acetate (pH4.5; 10 mM)–acetonitrile (25:75 v/v). The method was
linear and validated over the concentration range of 0.2–40.0 ng/mL for simvastatin and 0.05–15.0 ng/mL for
ezetimibe. The transitions selected were m/z 408.3-271.1 and m/z 412.0-275.10 for ezetimibe and
ezetimibe d4, and m/z 419.30-285.20 and m/z 425.40-199.20 for simvastatin and simvastatin d6. Intra- and
inter-batch precisions for ezetimibe were 1.6–14.8% and 2.1–13.4%; and for simvastatin 0.94–9.56% and
0.79–12%, respectively. The proposed method was sensitive, selective, precise and accurate for the
quantiﬁcation of ezetimibe and simvastatin simultaneously in rat plasma. The method was successfully
applied to a pharmacokinetic study by oral co-administration of ezetimibe and simvastatin in SD rats.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Else
2
855775.
(P. Katakam).
n Jiaotong University. 1. Introduction
Hypercholesterolemia is one of the important risk factors for coronary
artery disease and also a major cause of death in the industrialized
and highly developed countries. Reduction in the total cholesterol andvier B.V. All rights reserved.
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coronary artery disease. Serum cholesterol is obtained both endogen-
ously from biosynthesis and exogenously from the diet. Combination
therapy with two or more hypolipidemics that act by different
mechanisms is often more useful than treatment with single agent.
Ezetimibe (EZE) localizes in the small intestine and acts at the brush
border, thus inhibits the passage of dietary and biliary cholesterol
across the intestinal wall [1]. Simvastatin (SV) hydrolyzes to form a β,
Δ-dihydroxy acid, which is an active metabolite, structurally similar to
β-hydroxy-β-methylglutaryl coenzyme A (HMG-Co A), a key inter-
mediate in cholesterol biosynthesis. Hydrolyzed simvastatin competes
for HMG-CoA reductase, this leads to decrease in cholesterol
biosynthesis [2]. Co-administration of EZE and SV resulted in a dose
dependent reduction of low density lipoprotein (LDL) and total
cholesterol with no effect on high density lipoprotein (HDL)
cholesterol and triglycerides. Thus combination therapy exerts syner-
gistic effect by different mechanisms in reducing serum cholesterol
derived from different routes. Hence co-administration of these two
agents has beneﬁcial effects in the treatment of hypercholesterolemia
and thus in reducing the risk of coronary artery disease [3].
During preclinical and clinical investigations large numbers of
biological samples are generated for quantitative analysis. This
demands an efﬁcient, reliable and rapid analytical method for the
analysis of such a large pool of samples. Liquid chromatography–
mass spectroscopy (LC–MS/MS) is one such analytical techniques
which meets the above criteria. Several methods were reported for the
quantiﬁcation of EZE separately in biological ﬂuids by LC–MS/MS
[4,5], gas chromatography–mass spectroscopy [6], and with its phases
I and II metabolites by high performance liquid chromatography
(HPLC) with UV detection [7]. Similar methods were reported for the
determination of SV individually in plasma samples by HPLC [8],
with simvastatin acid [9–11] and with metoprolol [12] by LC–MS/
MS. The available methods are used either for the determination of
SV or EZE individually or for the determination of these analytes
along with its metabolites or with other drugs. Simultaneous
determination of EZE and SV from biological ﬂuids has not been
reported in the literature. Hence the aim of our work was to develop a
simple, sensitive, rapid and validated bioanalytical method for the
simultaneous quantiﬁcation of EZE and SV in rat plasma.
Present work focuses on the development of rapid and reliable
bioanalytical method for simultaneous quantiﬁcation of EZE and SV
in rat plasma using EZE d4 and SV d6 as deuterated internal standards
respectively. Further this method was applied to a pharmacokinetic
(PK) study in rats. In terms of combination EZE and SV were ionized
efﬁciently in the negative and positive ionization modes, respectively.
This demands the switch of electron spray ionization mode from
negative to positive during analysis and separate internal standard for
each analyte. The developed method is expected to provide a
benchmark for pharmacokinetic, bioavailability and bioequivalence
studies of EZE and SV.2. Materials and methods
2.1. Chemicals and reagents
The reference standards EZE and SV were obtained from Dr. Reddy
Labs, Hyderabad, India and internal standards of deuterium isotopes;
EZE d4, and SV d6 were purchased from Sigma Aldrich, India.
HPLC grade ammonium acetate and acetonitrile were purchased
from Merck, India. All other chemicals are of AR grade from
Merck, India.2.2. Instrumentation
Liquid chromatographic system consisting of an Agilent 1200
series, an auto sampler and API 4000 Q Trap mass spectrometer,
electrospray ionization (ESI) source in the negative as well as the
positive ion mode for both analytes and internal standards (IS)
with multiple reaction monitoring (MRM) was employed during
the study.
2.3. Chromatographic conditions
Agilent Eclipse XDB-C18 column (4.6 mm 150 mm, 5 mm) with
a column oven temperature of 45.0 1C was employed. The mobile
phase used was ammonium acetate (pH 4.5; 10 mM)–acetonitrile
(25:75, v/v). The ﬂow rate was 0.75 mL/min and injection volume
was 20 mL with a total run time of 7 min.
2.4. Mass spectrometric conditions
ESI in both positive and negative ionization modes with MRM
was employed to acquire the mass spectra. In mass spectrometry,
the parameters including temperature, ﬂow rate of curtain gas and
collision gas and collision energy were optimized.
2.5. Preparation of solutions
Primary stock solutions of 1 mg/mL each of EZE, EZE d4, SV and
SV d6 were prepared in methanol and stored at 2–8 1C. From primary
stock solutions, stock dilutions of EZE ranging from 2.5 to 750 ng/mL
and SV from 10 to 2000 ng/mL were made with 60% acetonitrile in
water (diluent). From this, a series of eight mixed calibration curve
(CC) standards were prepared. Concentrations ranging from 0.05 to
15.0 ng/mL for EZE (0.05, 0.1, 0.25, 0.75, 2.0, 5.0, 10.0 and 15.0 ng/
mL) and 0.2 to 40.0 ng/mL for SV (0.2, 0.5, 1.0, 2.5, 5.0, 10.0, 20.0
and 40.0 ng/mL) were prepared in K2EDTA (potassium salt of
ethylene diamine tetra acetic acid) rat plasma using above stock
dilutions and labeled them as CC1 to CC8. QC samples were prepared
at the concentrations of 0.05, 0.15, 1.00, 6.00 and 12.00 ng/mL for
EZE and 0.2, 0.6, 2.0, 15.0 and 32.0 ng/mL for SV in K2EDTA rat
plasma and labeled them as lower limit of quantitation (LLOQ), low
concentration (LQC), medium concentration 1 (MQC1), medium
concentration 2 (MQC2), and high concentration (HQC) quality
control samples, respectively. This IS stock solution was diluted with
60% acetonitrile in water solution to get a concentration of 0.5 mg/mL
of EZE d4 and 0.25 mg/mL of SV d6.
2.6. Extraction procedure
The blank, calibration curve standards and quality control samples
were withdrawn from the freezer and allowed to thaw. After post-
thawing, the samples were vortexed to ensure complete mixing of
the contents. 20 mL of 60% acetonitrile in water was added to a
vial labeled as plasma blank. 20 μL each of SV d6 (0.250 mg/mL)
and EZE d4 (0.50 mg/mL) were added to all pre-labeled vials and
labeled as plasma blank with IS, calibration curve standards (CC1–
CC8) and quality control samples (LLOQ, LQC, MQC1, MQC2
and HQC). To these vials, either 100 μL of blank plasma or spiked
plasma was added as per the requirement. The samples were
vortexed to ensure complete mixing of the contents. To all the
vials, 2.5 mL of tertiary butyl methyl ether (TBME) was added and
were kept on shaker for 15 min and centrifuged at 4000 rpm at
S.R. Karanam et al.28820 1C for 10 min. The supernatant organic layer was transferred to
pre-labeled vials. This layer was evaporated under a stream of
nitrogen gas at 45 1C. The residue was reconstituted with 0.20 mL
of mobile phase for plasma samples. These samples were vortexed
and loaded in auto-injector vials. 20 mL of samples was injected
onto LC–MS/MS system.2.7. Method validation
To meet its requirements, the developed bio-analytical method
was validated according to FDA guidance [13]. The selectivity
was determined by checking the blank plasma obtained from
six lots.
Samples were processed according to the above procedure and
injected into the LC–MS/MS system in order to determine the
extent of interference from endogenous sample components at the
retention times of EZE, EZE d4, SV and SV d6. Any interfering
compounds those eluted along with the analyte (free ezetimibe/
simvastatin) were compared with the respective mean peak area
responses of six extracted LLOQ samples (prepared from any one
of the six plasma lots).
2.7.1. Linearity
To determine linearity, eight mixed calibration curve standards
were prepared over the concentration range of 0.05–15.0 ng/mL
for EZE and 0.20–40.0 ng/mL for SV (n¼3). Calibration curves
were plotted between ratios of analyte to IS concentration on the
x-axis versus peak area ratio on the y-axis. The lowest concentra-
tion on the calibration curve with the detector response ﬁve times
larger than blank plasma response (precision of r20% and
accuracy of 720%) was considered as LLOQ.
2.7.2. Recovery
Recovery of EZE and SV was determined at low, medium and
high QC concentrations (n¼6) by comparing responses from
extracted plasma samples with that from unextracted plasma
samples. Recovery of internal standards EZE d4 and SV d6 was
also determined in the same way.
2.7.3. Accuracy and precision
Accuracy and precision was determined for both intra- and inter-
batch QC samples. Intra-batch accuracy and precision was
determined by analyzing six replicates within the same batch for
all the ﬁve QC samples. Inter-batch accuracy and precision was
determined by analyzing six replicates (from each batch) of QC
samples of two different batches. Precision was determined and
expressed as percent coefﬁcient of variation (%CV) and it should
be r15% in all cases except at LLOQ, where it should not exceed
20%. Accuracy was determined by comparing the mean value with
the actual value and it should be715% of the actual value except
at LLOQ, where it should not exceed 720% of the actual
value [13].
2.7.4. Matrix effect
Matrix effect was determined for both the analytes at low and high
QC concentrations by spiking the samples to the extracted plasma.
Matrix factor (MF) was determined by comparing peak response in
the presence of matrix ions (spiked samples) with that in the
absence of matrix ions (aqueous standards at low and high QC
concentrations).MF¼ Peak response in the presence of matrix ions
Mean peak response in the absence of matrix ions
2.7.5. Stability studies
Stability studies were carried out for low and high QC samples as
long term and short term stability, freeze–thaw stability and
stability of processed samples [13]. Long term and short term
stability were determined by keeping the samples at 20 1C for 1
month and at room temperature for 6 h. Freeze–thaw stability was
assessed by storing the samples at 20 1C for 24 h and then
thawing at room temperature. After such three freeze–thaw cycles
the stability was determined. Stability of the processed samples
was determined by keeping the samples in an auto sampler at
20 1C for 24 h. In all cases the samples are said to be stable if the
nominal values obtained are within 715% of the back calculated
calibration curve concentrations.
2.8. Application of LC–MS/MS method to a pharmacokinetic
study
The developed LC–MS/MS method was successfully applied to a
pharmacokinetic study by co-administration of EZE and SV to six
male Sprague-Dawley (SD) rats by oral route using BD syringe
attached with oral gavage needle (size 18) at the dose of 1 and
8 mg/kg body weight, respectively. Required quantity of test item
(3.03 mg EZE and 30.17 mg SV) was accurately weighed and
transferred to a mortar and triturated with 2% (w/w) Tween 80
using a pestle to make a smooth paste. Then, 0.5% (w/w)
carboxymethyl cellulose (CMC) was gradually added and sus-
pended to make a required concentration (1 mg/mL of EZE and
8 mg/mL of SV). The ﬁnal suspension was kept under continuous
stirring till the dose administration.
Approximately 0.25 mL of blood samples from each anesthetized
(isoﬂurane) rat at pre-determined time intervals was collected from
the retro-orbital plexus using a capillary tube into pre-labeled
eppendorf tubes containing 10% of K2EDTA anticoagulant
(20 mL). The time intervals for the sample collection were 0
(Predose), 0.5, 1, 2, 4, 6, 8, 12, 24 and 48 h (post-dose). The total
blood volume collected from each rat was 2.2–2.4 mL which does
not exceed the maximal recommended blood volume of 20%
(3.2 mL for a 250 g body weight rat) [14]. Plasma was obtained
by centrifuging blood samples at 3000 rpm for 10 min. The obtained
plasma samples were transferred into pre-labeled microcentrifuge
tubes and stored at 20 1C. All the samples were analyzed by the
developed method. Pharmacokinetic parameters were calculated by
non-compartmental analysis by using Win Nonlins 6.2 software.
Concentrations obtained from the above bio-analytical method were
compiled.3. Results and discussion
3.1. Method optimization
Chromatographic conditions were optimized by using different
ratios of acetonitrile-buffer and methanol-buffer as mobile phase
and by employing various columns such as Hypersil, Chromosil
and Agilent Eclipse. Better chromatographic separation was
achieved with Agilent Eclipse XBD-C18 column using mobile
phase consisting of a mixture of ammonium acetate (pH 4.5;
Ezetimibe and simvastatin in rat plasma by LC-ESI–MS/MS 28910 mM)–acetonitrile (25:75, v/v). These conditions provided a
good peak shape to both analytes and IS and signal to noise ratio
was also good at LLOQ.Table 1 Optimized MRM conditions of mass spectroscopy applied
Parameter SV
Declustering potential 60
Entrance potential 10
Collision energy 18
Collision cell exit potential 8
Ion spray voltage 5500
All values are in volts.
Fig. 1 Product ions of (A) ezetimibe (EZE) (MH), (B) ezetimibe d4 (E
(SV d6) (MþH)þ.Quadrupole mass spectrometer was employed; here parent ion
was selected by ﬁrst quadrupole (Q1) followed by fragmentation
of the parent ion with N2 gas in the collision chamber (Q2) andin the method development.
SV d6 EZE EZE d4
60 67 67
10 10 10
18 20 20
8 6 6
5500 4500 4500
ZE d4) (MH), (C) simvastatin (SV) (MþH)þ and (D) simvastatin d6
S.R. Karanam et al.290then full product ion scan in the third quadrupole (Q3). In mass
spectrometry, the parameters including temperature, ﬂow rate of
curtain gas (20 psi), collision gas (medium), gas-1 (35.0 psi), gas-2
(45.0 psi) and temperature (450.0 1C) were optimized to obtain
maximum response of the fragment ion. The optimized MRM
conditions of mass spectroscopy applied in the method develop-
ment are shown in Table 1.
Internal standard selected should always have similar chromato-
graphic and ionization properties, and recovery of the analyte.
Based on these properties deuterated analogs of EZE and SV (EZE
d4 and SV d6) were chosen as internal standards. EZE and EZE d4
were ionized efﬁciently in the negative ionization mode
and precursor ions formed were of (MH). The SV and SV d6
were ionized efﬁciently in the positive ionization mode and
(MþH)þ ions were formed. Hence there was a switch from
negative to positive ionization mode at retention time (RT)
3.01 min. In the case of EZE and EZE d4 fragmentation pattern
is the same and it takes place at azetidine ring; and the formation
of product ion was at m/z 271.10 and 275.10 amu respectively.
Fragmentation of SV takes places at the ester side chain [15],
followed by loss of water molecule leads to formation of product
ion at m/z 285.20. For SV d6 further loss of the neutral moleculeFig. 2 Chromatograms of spiked ezetimibe with rat plasma. (A) blank plasm(CH3COOH or CH2QCQO and H2O) leads to the formation of
a product ion at m/z 199.20. Parent to product ion transitions
selected were m/z 408.3-271.10 and m/z 412.0-275.10 for EZE
and EZE d4 respectively; m/z 419.30-285.20 and m/z 425.40-
199.20 for SV and SV d6 respectively, as shown in Fig. 1. Total
chromatographic runtime was 7.0 min with RT of 2.32 and
2.31 min for EZE and EZE d4; 5.98 and 5.91 min for SV and
SV d6 respectively, as shown in Figs. 2 and 3.
ESI in both positive and negative modes was employed to detect
both analytes. But the presence of endogenous sample components
may affect the ionization of analytes either by ion suppression or
enhancement during ESI. This in turn affects the sensitivity,
precision and recovery of the analyte. The extent of this effect
mainly depends upon the extraction procedure and is also com-
pound dependent. Compared to protein precipitation LLE is helpful
in producing a clean sample spectroscopically and avoids introduc-
tion of plasma components and non volatile materials. Hence LLE
was employed to extract the analyte and IS from plasma. Different
solvents like hexane, dichloromethane, diethyl ether and TBME
were tried as solvents. Efﬁcient extraction of both analytes and IS
was obtained by addition of 2.5 mL of TBME to 100 mL of plasma.
Clean chromatograms were obtained with no signiﬁcant matrixa, (B) LLOQ of ezetimibe, (C) ULOQ of ezetimibe and (D) ezetimibe d4.
Ezetimibe and simvastatin in rat plasma by LC-ESI–MS/MS 291effects as shown in Figs. 2 and 3. Recoveries of analyte and IS were
consistent and reproducible. LLE procedure adopted using TBME
was found to be suitable for simultaneous extraction of all the four
components from rat plasma.Fig. 3 Chromatograms of spiked simvastatin with rat plasma (A) blan
(D) simvastatin d6.
Table 2 Recovery of EZE and SV from matrix samples (n¼6).
Analyte Conc. (ng/mL) Mean recove
EZE 0.15 0.14
6.0 5.79
12.0 11.27
SV 0.6 0.51
15.0 14.02
32.0 31.2
EZE d4 500.0 451.4
SV d6 250.0 229.9
aCoefﬁcient of variation.
bRelative error.3.2. Method validation
Selectivity of the method was determined by comparing chroma-
tograms of blank plasma from six different lots. No signiﬁcantk plasma, (B) LLOQ of simvastatin, (C) ULOQ of simvastatin and
ry (ng/mL) CV (%)a RE (%)b
11.49 6.67
8.12 3.50
7.34 6.10
5.05 15.00
1.73 6.50
2.37 2.50
6.32 9.70
7.10 8.10
S.R. Karanam et al.292interfering peaks were observed at the retention times of analytes
and IS. The peak areas of blank samples at the RT of analytes
were r20% and those at RT of IS were r5% compared to peak
area of extracted LLOQ samples. Chromatograms of blank plasma,
blank plasma spiked with EZE, SV, EZE d4 and SV d6 are shown
in Figs. 2 and 3.
The method was linear over the range of 0.20–40.0 ng/mL for
SV and 0.05–15.0 ng/mL for EZE. A straight line ﬁt was made
through the data points by 1/x2 weighting method and was found
to be best ﬁt for EZE and SV. The regression equations were
calculated as y¼0.0203xþ0.0000647 for EZE and y¼0.0214xþ
0.000901 for SV. The observed correlation coefﬁcient (R2) was
greater than 0.999 in both the cases. Hence the method is linear in the
stated range. The LLOQ of EZE and SV were 0.05 and 0.2 ng/mL
respectively. Such low concentrations are suitable for pre-clinical and
clinical PK studies.
The recovery of EZE and SV from rat plasma was determined
by comparing peak areas from extracted standard samples with
those from unextracted standard samples. The percentage recovery
of EZE was 93.9–96.5% and for SV it was 93.5–97.5%. The
percentage recovery of EZE d4 and SV d6 was 90.27% and
91.94% respectively. The results are shown in Table 2.
Both inter- and intra-batch precision and accuracy were
determined and expressed as %CV (coefﬁcient of variation) andTable 3 Intra- and inter-batch precision and accuracy of EZE and S
Analyte Conc. (ng/mL) Intra-batch
Amt. conc. 7SDa (ng/mL) CV (%)b
EZE 0.05 0.04970.004 8.16
0.15 0.16870.025 14.82
1.0 0.9370.02 2.21
6.0 5.6370.09 1.64
12.0 11.4370.28 2.42
SV 0.2 0.20670.002 9.56
0.6 0.61970.024 3.83
2.0 2.00270.019 0.96
15.0 14.5370.17 1.15
32.0 30.2270.28 0.94
aStandard deviation.
bCoefﬁcient of variation.
cRelative error.
Table 4 Matrix effect of EZE and SV in rat plasma (n¼6).
Analyte Conc. (ng/mL) Peak response ratio in the absence
of matrix ions
SV 0.6 0.0154
32 0.0304
EZE 0.15 0.0065
12 0.4943
aStandard deviation.
bCoefﬁcient of variation.% accuracy respectively. The %CV observed for EZE for the inter-
batch QC samples was 2.10–13.46% and for intra-batch QC
samples it was from 2.0% to 14.82%. The %CV observed for
SV in the inter-batch QC samples was ranged from 0.79% to
12.00% whereas in the intra-batch QC samples it was from 0.57%
to 12.39%. The % accuracy observed for EZE for inter- and intra-
batch QC samples was 92.9–108% and 92.9–112% respectively.
The % accuracy observed for SV for inter- and intra-batch QC
samples ranged from 94.69% to 102.50% and 92% to 103%
respectively. The results are summarized in Table 3.
To determine the extent of interference between analytes and
biological matrix, the overall precision of matrix factor (MF) was
determined. The MF as calculated by the %CV was found to be
less than 15% for both analytes, which was within the acceptance
criteria. The results are shown in Table 4.
Stability studies were performed under a variety of conditions
and the results are given in Table 5. The analytes were stable at
room temperature (25–30 1C) for a minimum of 6 h; unaltered to a
signiﬁcant extent at 20 1c for 1 month and good % recoveries
were obtained. In an auto sampler kept at 20 1C samples of
analytes were stable for 24 h. The freeze–thaw stability results
indicated that analytes were stable for three cycles. Results showed
that plasma samples under study can be freezed and thawed
without compromising the reliability of the samples.V (n¼6).
Inter-batch
RE (%)c Amt. conc. 7SDa (ng/mL) CV (%)b RE (%)c
2 0.04970.003 6.12 2
12 0.16270.220 13.46 8
7.2 0.9370.02 2.16 7.1
6.08 5.7270.12 2.10 4.67
4.77 11.4670.24 2.13 4.5
3.17 0.19570.023 12.00 2.5
3.2 0.61570.023 3.85 2.5
0.1 1.98870.035 1.77 0.6
3.16 14.5670.13 0.89 2.93
5.57 30.3070.24 0.79 2.19
Peak response ratio in the presence
of matrix ions
Matrix
factor7SDa
CV (%)b
0.0307 1.00970.008 0.76
1.5941 0.98270.013 1.32
0.0063 0.96470.039 3.99
0.4949 1.00170.013 1.27
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Blood was collected for 48 h at different time points and the plasma
samples were analyzed using the developed method. The following
pharmacokinetic parameters were primarily calculated by non-
compartmental analysis and the results are shown in Table 6. Peak
plasma concentration attained by the drug (Cmax), time required to
attain peak plasma concentration (Tmax), area under the curve
AUC(0t) and AUC(01), plasma clearance (Clf) and time it takes
for a test item undergoing decay to decrease by half (t1/2) were
determined. Chromatograms in rat plasma after oral administration of
EZE and SV and plasma concentration versus time proﬁles are given
in Fig. 4. Analytes were detectable in the blood for up to 8–12 h only,
after that they were not detectable and attained zero concentrations.
Most of the PK parameters were variable and also standard deviation
values were also higher due to intra and inter-animal variability.
Ezetimibe is rapidly absorbed and extensively metabolized and oral
bioavailability is low, due to extensive conjugation and biliary
excretion. Thereby, inter and intra-animal variability often seems with
ezetimibe in rats [16]. Simvastatin is a lactone which is readily
hydrolyzed to the corresponding hydroxyacid and following
oral administration simvastatin undergoes extensive ﬁrst-pass effect
in the liver thereby availability of the drug in the systemic
circulation is very low. The developed LC–MS/MS method wasTable 5 Stability data of EZE and SV of samples maintained at var
Stability studies Analyte Conc. spik
Short term (6 h) SV 0.6
32.0
EZE 0.15
12.0
Long term (20 1C, 1 month) SV 0.6
32.0
EZE 0.15
12.0
Freeze–thaw (20 1C and RT, 24 h and 3 cycles) SV 0.6
32.0
EZE 0.15
12.0
Processed samples (24 h) SV 0.6
32.0
EZE 0.15
12.0
aStandard deviation.
bRelative error.
cCoefﬁcient of variation.
Table 6 Pharmacokinetic parameters following oral co-administratio
Parameter EZE (Mea
Cmax (ng/mL) 0.2670.1
Tmax (h 4.079.5
AUC(0t) (ng h/mL) 1.7571.6
AUC(01) (ng h/mL) 2.3373.9
Clf (mL/h/kg) 0.3570.2
t1/2 (h) 0.1577.6
SD: Standard deviation.successfully applied to a pharmacokinetic study following co-
administration of EZE and SV (1 mg/kg and 8 mg/kg respectively)
in SD rats.4. Conclusions
The combination of EZE and SV is widely available and also used in
the treatment of hypercholesterolemia. There is no published literature
found for the simultaneous estimation of these drugs from biological
samples. Therefore development of such methods is in most need for
the quantiﬁcation of these drugs simultaneously. Proposed LC–MS/MS
method in electron spray ionization with MRM mode was found to be
rapid, sensitive, and reliable for the quantiﬁcation of EZE and SV from
rat plasma simultaneously. The developed method was successfully
applied to a pharmacokinetic study in rats. This method can be applied
in clinical studies, bioavailability and bioequivalence studies.Acknowledgments
Authors are thankful to the Vimta Life Sciences, Genome Valley,
Hyderabad, India for their technical and laboratory assistance in
carrying out the project.ious conditions (n¼6).
ed (ng/mL) Mean recovery 7SDa (ng/mL) RE (%)b CV (%)c
0.5470.04 9.50 8.10
29.9071.68 6.56 5.60
0.1470.01 6.66 4.92
10.8470.76 9.66 6.99
0.5470.03 9.33 6.10
29.0271.83 9.30 6.31
0.1470.01 6.66 5.09
11.0370.57 8.08 5.17
0.5470.04 10.16 7.58
30.6171.16 4.34 3.80
0.14370.004 4.66 3.07
10.8970.62 9.25 5.65
0.54770.035 8.83 6.51
29.6371.04 7.25 3.52
0.14070.005 6.66 3.94
10.8970.62 9.27 5.71
n of EZE (1 mg/kg) and SV (8 mg/kg) to male SD rats (n¼6).
n7SD) SV (Mean7SD)
4 7.5875.50
0.9270.59
8 11.12718.99
7 11.2577.47
5 0.9270.45
8 0.4370.60
Fig. 4 Chromatograms in rat plasma (A) ezetimibe and (B) simvastatin after oral administration of 1 mg/kg of ezetimibe and 8 mg/kg
of simvastatin and mean plasma concentrations of (C) ezetimibe and (D) simvastatin during pharmacokinetic study (means7SD, n¼6).
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